<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00127192</url>
  </required_header>
  <id_info>
    <org_study_id>0431-044</org_study_id>
    <secondary_id>MK0431-044</secondary_id>
    <secondary_id>2005_037</secondary_id>
    <nct_id>NCT00127192</nct_id>
  </id_info>
  <brief_title>A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)</brief_title>
  <official_title>Sitagliptin (MK0431) Late Phase II Double-Blind Dose-Response Study - Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine the efficacy and safety of an investigational drug
      in patients with type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in HbA1c at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the Week 0 HbA1c percent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glycosylated Albumin at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Change from baseline at Week 12 is defined as Week 12 minus Week 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Change from baseline at Week 12 is defined as Week 12 minus Week 0.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">363</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo QD 12-week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg QD 12-week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg QD 12-week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg QD 12-week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg QD 12-week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin phosphate</intervention_name>
    <description>sitagliptin phosphate 25 mg, 50 mg, 100 mg QD, or 200 mg QD 12-weeks.</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <other_name>MK0431</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: placebo (unspecified)</intervention_name>
    <description>placebo QD 12-weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with type 2 diabetes mellitus

        Exclusion Criteria:

          -  Patients with type 1 diabetes mellitus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <results_reference>
    <citation>Iwamoto Y, Taniguchi T, Nonaka K, Okamoto T, Okuyama K, Arjona Ferreira JC, Amatruda J. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J. 2010;57(5):383-94. Epub 2010 Mar 24.</citation>
    <PMID>20332588</PMID>
  </results_reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2005</study_first_submitted>
  <study_first_submitted_qc>August 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2005</study_first_posted>
  <results_first_submitted>August 18, 2009</results_first_submitted>
  <results_first_submitted_qc>September 24, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 25, 2009</results_first_posted>
  <last_update_submitted>May 20, 2015</last_update_submitted>
  <last_update_submitted_qc>May 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Phase II.
First patient in: 11 July 2005. Last patient, last visit: 8 March 2006.
The study was conducted at 97 centers in Japan.</recruitment_details>
      <pre_assignment_details>Patients 20-75 years of age with type 2 diabetes mellitus and inadequate glycemic control (HbA1c ≥6.5% and &lt;10% at Week -2) were eligible for randomization following at least 8 weeks of diet/exercise and antihyperglycemic agent (AHA) wash-off (for patients previously on an AHA), including a 2-week placebo run-in.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin 25 mg QD</title>
          <description>The Sitagliptin 25 mg group includes data from all patients randomized to receive treatment with sitagliptin 25 mg orally once daily (QD=once daily).</description>
        </group>
        <group group_id="P2">
          <title>Sitagliptin 50 mg QD</title>
          <description>The Sitagliptin 50 mg group includes data from all patients randomized to receive treatment with sitagliptin 50 mg orally once daily (QD=once daily).</description>
        </group>
        <group group_id="P3">
          <title>Sitagliptin 100 mg QD</title>
          <description>The Sitagliptin 100 mg group includes data from all patients randomized to receive treatment with sitagliptin 100 mg orally once daily (QD=once daily).</description>
        </group>
        <group group_id="P4">
          <title>Sitagliptin 200 mg QD</title>
          <description>The Sitagliptin 200 mg group includes data from all patients randomized to receive treatment with sitagliptin 200 mg orally once daily (QD=once daily).</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>The Placebo group includes data from all patients randomized to receive treatment with matching placebo orally once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80">Study enrolled slightly more than the target of N=70</participants>
                <participants group_id="P2" count="72">Study enrolled slightly more than the target of N=70</participants>
                <participants group_id="P3" count="70">Study enrolled as per the target of N=70</participants>
                <participants group_id="P4" count="68">Study enrolled slightly less than the target of N=70</participants>
                <participants group_id="P5" count="73">Study enrolled slightly more than the target of N=70</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="71"/>
                <participants group_id="P3" count="68"/>
                <participants group_id="P4" count="67"/>
                <participants group_id="P5" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse event in pre-treatment period</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin 25 mg QD</title>
          <description>The Sitagliptin 25 mg group includes data from all patients randomized to receive treatment with sitagliptin 25 mg orally once daily (QD=once daily).</description>
        </group>
        <group group_id="B2">
          <title>Sitagliptin 50 mg QD</title>
          <description>The Sitagliptin 50 mg group includes data from all patients randomized to receive treatment with sitagliptin 50 mg orally once daily (QD=once daily).</description>
        </group>
        <group group_id="B3">
          <title>Sitagliptin 100 mg QD</title>
          <description>The Sitagliptin 100 mg group includes data from all patients randomized to receive treatment with sitagliptin 100 mg orally once daily (QD=once daily).</description>
        </group>
        <group group_id="B4">
          <title>Sitagliptin 200 mg QD</title>
          <description>The Sitagliptin 200 mg group includes data from all patients randomized to receive treatment with sitagliptin 200 mg orally once daily (QD=once daily).</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>The Placebo group includes data from all patients randomized to receive treatment with matching placebo orally once daily.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="72"/>
            <count group_id="B3" value="70"/>
            <count group_id="B4" value="68"/>
            <count group_id="B5" value="73"/>
            <count group_id="B6" value="363"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.9" spread="7.9"/>
                    <measurement group_id="B2" value="60.2" spread="9.4"/>
                    <measurement group_id="B3" value="58.3" spread="9.5"/>
                    <measurement group_id="B4" value="60.6" spread="7.7"/>
                    <measurement group_id="B5" value="60.2" spread="8.0"/>
                    <measurement group_id="B6" value="59.8" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="50"/>
                    <measurement group_id="B6" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Plasma Glucose (FPG)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145.7" spread="37.6"/>
                    <measurement group_id="B2" value="144.3" spread="29.0"/>
                    <measurement group_id="B3" value="142.6" spread="31.8"/>
                    <measurement group_id="B4" value="148.4" spread="33.3"/>
                    <measurement group_id="B5" value="156.5" spread="35.1"/>
                    <measurement group_id="B6" value="147.5" spread="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated albumin</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.5" spread="3.9"/>
                    <measurement group_id="B2" value="22.0" spread="4.2"/>
                    <measurement group_id="B3" value="21.9" spread="4.5"/>
                    <measurement group_id="B4" value="21.9" spread="3.9"/>
                    <measurement group_id="B5" value="23.7" spread="4.5"/>
                    <measurement group_id="B6" value="22.2" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c (HbA1c)</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.5" spread="0.8"/>
                    <measurement group_id="B2" value="7.6" spread="0.8"/>
                    <measurement group_id="B3" value="7.6" spread="0.8"/>
                    <measurement group_id="B4" value="7.7" spread="0.8"/>
                    <measurement group_id="B5" value="7.7" spread="0.9"/>
                    <measurement group_id="B6" value="7.6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glycosylated Albumin at Week 12</title>
        <description>Change from baseline at Week 12 is defined as Week 12 minus Week 0.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The Full Analysis Set (FAS) included all patients with a baseline value and ≥1 post-baseline value for this outcome. For FAS patients with no data at Week 12, the last non-baseline observed measurement was carried forward to Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 25 mg QD</title>
            <description>The Sitagliptin 25 mg group includes data from all patients randomized to receive treatment with sitagliptin 25 mg orally once daily (QD=once daily).</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin 50 mg QD</title>
            <description>The Sitagliptin 50 mg group includes data from all patients randomized to receive treatment with sitagliptin 50 mg orally once daily (QD=once daily).</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin 100 mg QD</title>
            <description>The Sitagliptin 100 mg group includes data from all patients randomized to receive treatment with sitagliptin 100 mg orally once daily (QD=once daily).</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 200 mg QD</title>
            <description>The Sitagliptin 200 mg group includes data from all patients randomized to receive treatment with sitagliptin 200 mg orally once daily (QD=once daily).</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>The Placebo group includes data from all patients randomized to receive treatment with matching placebo orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Albumin at Week 12</title>
          <description>Change from baseline at Week 12 is defined as Week 12 minus Week 0.</description>
          <population>The Full Analysis Set (FAS) included all patients with a baseline value and ≥1 post-baseline value for this outcome. For FAS patients with no data at Week 12, the last non-baseline observed measurement was carried forward to Week 12.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" lower_limit="-2.4" upper_limit="1.5"/>
                    <measurement group_id="O2" value="-2.6" lower_limit="-3.1" upper_limit="2.2"/>
                    <measurement group_id="O3" value="-2.6" lower_limit="-3.0" upper_limit="2.1"/>
                    <measurement group_id="O4" value="-2.9" lower_limit="-3.4" upper_limit="2.5"/>
                    <measurement group_id="O5" value="0.7" lower_limit="0.2" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity among pairwise comparisons of sitagliptin groups against placebo was adjusted by Bonferroni method in post-hoc manner.</p_value_desc>
            <method>Pairwise comparison based on ANCOVA</method>
            <method_desc>ANCOVA model with terms of treatment, prior antihyperglycemic medication status and baseline was used for pairwise comparison</method_desc>
            <param_type>Least-squares Mean Difference</param_type>
            <param_value>-3.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.3</ci_lower_limit>
            <ci_upper_limit>-3.0</ci_upper_limit>
            <estimate_desc>ANCOVA model with terms of treatment, prior antihyperglycemic medication status and baseline was used to estimate difference of two groups and its 95% confidence interval</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity among pairwise comparisons of sitagliptin groups against placebo was adjusted by Bonferroni method in post-hoc manner.</p_value_desc>
            <method>Pairwise comparison based on ANCOVA</method>
            <method_desc>ANCOVA model with terms of treatment, prior antihyperglycemic medication status and baseline was used for pairwise comparison</method_desc>
            <param_type>Least-squares Mean Difference</param_type>
            <param_value>-3.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>-2.6</ci_upper_limit>
            <estimate_desc>ANCOVA model with terms of treatment, prior antihyperglycemic medication status and baseline was used to estimate difference of two groups and its 95% confidence interval</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity among pairwise comparisons of sitagliptin groups against placebo was adjusted by Bonferroni method in post-hoc manner.</p_value_desc>
            <method>Pairwise comparison based on ANCOVA</method>
            <method_desc>ANCOVA model with terms of treatment, prior antihyperglycemic medication status and baseline was used for pairwise comparison</method_desc>
            <param_type>Least-squares Mean Difference</param_type>
            <param_value>-3.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>-2.7</ci_upper_limit>
            <estimate_desc>ANCOVA model with terms of treatment, prior antihyperglycemic medication status and baseline was used to estimate difference of two groups and its 95% confidence interval</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity among pairwise comparisons of sitagliptin groups against placebo was adjusted by Bonferroni method in post-hoc manner.</p_value_desc>
            <method>Pairwise comparison based on ANCOVA</method>
            <method_desc>ANCOVA model with terms of treatment, prior antihyperglycemic medication status and baseline was used for pairwise comparison</method_desc>
            <param_type>Least-squares Mean Difference</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.2</ci_lower_limit>
            <ci_upper_limit>-2.0</ci_upper_limit>
            <estimate_desc>ANCOVA model with terms of treatment, prior antihyperglycemic medication status and baseline was used to estimate difference of two groups and its 95% confidence interval</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in HbA1c at Week 12</title>
        <description>HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the Week 0 HbA1c percent.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The Full Analysis Set (FAS) included all patients with a baseline value and ≥1 post-baseline value for this outcome. For FAS patients with no data at Week 12, the last non-baseline observed measurement was carried forward to Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 25 mg QD</title>
            <description>The Sitagliptin 25 mg group includes data from all patients randomized to receive treatment with sitagliptin 25 mg orally once daily (QD=once daily).</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin 50 mg QD</title>
            <description>The Sitagliptin 50 mg group includes data from all patients randomized to receive treatment with sitagliptin 50 mg orally once daily (QD=once daily).</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin 100 mg QD</title>
            <description>The Sitagliptin 100 mg group includes data from all patients randomized to receive treatment with sitagliptin 100 mg orally once daily (QD=once daily).</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 200 mg QD</title>
            <description>The Sitagliptin 200 mg group includes data from all patients randomized to receive treatment with sitagliptin 200 mg orally once daily (QD=once daily).</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>The Placebo group includes data from all patients randomized to receive treatment with matching placebo orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c at Week 12</title>
          <description>HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the Week 0 HbA1c percent.</description>
          <population>The Full Analysis Set (FAS) included all patients with a baseline value and ≥1 post-baseline value for this outcome. For FAS patients with no data at Week 12, the last non-baseline observed measurement was carried forward to Week 12.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" lower_limit="-0.52" upper_limit="0.29"/>
                    <measurement group_id="O2" value="-0.71" lower_limit="-0.83" upper_limit="0.59"/>
                    <measurement group_id="O3" value="-0.69" lower_limit="-0.81" upper_limit="0.56"/>
                    <measurement group_id="O4" value="-0.76" lower_limit="-0.89" upper_limit="0.64"/>
                    <measurement group_id="O5" value="0.28" lower_limit="0.16" upper_limit="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Tukeys linear trend test based on ANCOVA</method>
            <method_desc>Linear contrast including all groups was tested using ANCOVA model with terms of treatment, prior antihyperglycemic medication status and baseline</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment was done between trend test of primary analysis and pairwise comparisons, but the multiplicity among pairwise comparisons of sitagliptin groups against placebo was adjusted by Bonferroni method in post-hoc manner.</p_value_desc>
            <method>Pairwise comparison based on ANCOVA</method>
            <method_desc>ANCOVA model with terms of treatment, prior antihyperglycemic medication status and baseline was used for pairwise comparison</method_desc>
            <param_type>Least-squares Mean Difference</param_type>
            <param_value>-1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.21</ci_lower_limit>
            <ci_upper_limit>-0.86</ci_upper_limit>
            <estimate_desc>ANCOVA model with terms of treatment, prior antihyperglycemic medication status and baseline was used to estimate difference of two groups and its 95% confidence interval</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment was done between trend test of primary analysis and pairwise comparisons, the multiplicity among pairwise comparisons of sitagliptin groups against placebo was adjusted by Bonferroni method in post-hoc manner.</p_value_desc>
            <method>Pairwise comparison based on ANCOVA</method>
            <method_desc>ANCOVA model with terms of treatment, prior antihyperglycemic medication status and baseline was used for pairwise comparison</method_desc>
            <param_type>Least-squares Mean Difference</param_type>
            <param_value>-0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.14</ci_lower_limit>
            <ci_upper_limit>-0.79</ci_upper_limit>
            <estimate_desc>ANCOVA model with terms of treatment, prior antihyperglycemic medication status and baseline was used to estimate difference of two groups and its 95% confidence interval</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment was done between trend test of primary analysis and pairwise comparisons, the multiplicity among pairwise comparisons of sitagliptin groups against placebo was adjusted by Bonferroni method in post-hoc manner.</p_value_desc>
            <method>Pairwise comparison based on ANCOVA</method>
            <method_desc>ANCOVA model with terms of treatment, prior antihyperglycemic medication status and baseline was used for pairwise comparison</method_desc>
            <param_type>Least-squares Mean Difference</param_type>
            <param_value>-0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.16</ci_lower_limit>
            <ci_upper_limit>-0.82</ci_upper_limit>
            <estimate_desc>ANCOVA model with terms of treatment, prior antihyperglycemic medication status and baseline was used to estimate difference of two groups and its 95% confidence interval</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment was done between trend test of primary analysis and pairwise comparisons, the multiplicity among pairwise comparisons of sitagliptin groups against placebo was adjusted by Bonferroni method in post-hoc manner.</p_value_desc>
            <method>Pairwise comparison based on ANCOVA</method>
            <method_desc>ANCOVA model with terms of treatment, prior antihyperglycemic medication status and baseline was used for pairwise comparison</method_desc>
            <param_type>Least-squares Mean Difference</param_type>
            <param_value>-0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.85</ci_lower_limit>
            <ci_upper_limit>-0.52</ci_upper_limit>
            <estimate_desc>ANCOVA model with terms of treatment, prior antihyperglycemic medication status and baseline was used to estimate difference of two groups and its 95% confidence interval</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose at Week 12</title>
        <description>Change from baseline at Week 12 is defined as Week 12 minus Week 0.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The Full Analysis Set (FAS) included all patients with a baseline value and ≥1 post-baseline value for this outcome. For FAS patients with no data at Week 12, the last non-baseline observed measurement was carried forward to Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 25 mg QD</title>
            <description>The Sitagliptin 25 mg group includes data from all patients randomized to receive treatment with sitagliptin 25 mg orally once daily (QD=once daily).</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin 50 mg QD</title>
            <description>The Sitagliptin 50 mg group includes data from all patients randomized to receive treatment with sitagliptin 50 mg orally once daily (QD=once daily).</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin 100 mg QD</title>
            <description>The Sitagliptin 100 mg group includes data from all patients randomized to receive treatment with sitagliptin 100 mg orally once daily (QD=once daily).</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 200 mg QD</title>
            <description>The Sitagliptin 200 mg group includes data from all patients randomized to receive treatment with sitagliptin 200 mg orally once daily (QD=once daily).</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>The Placebo group includes data from all patients randomized to receive treatment with matching placebo orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose at Week 12</title>
          <description>Change from baseline at Week 12 is defined as Week 12 minus Week 0.</description>
          <population>The Full Analysis Set (FAS) included all patients with a baseline value and ≥1 post-baseline value for this outcome. For FAS patients with no data at Week 12, the last non-baseline observed measurement was carried forward to Week 12.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.6" lower_limit="-14.0" upper_limit="5.3"/>
                    <measurement group_id="O2" value="-11.4" lower_limit="-16.0" upper_limit="6.8"/>
                    <measurement group_id="O3" value="-14.6" lower_limit="-19.2" upper_limit="9.9"/>
                    <measurement group_id="O4" value="-16.9" lower_limit="-21.6" upper_limit="12.1"/>
                    <measurement group_id="O5" value="6.3" lower_limit="1.7" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity among pairwise comparisons of sitagliptin groups against placebo was adjusted by Bonferroni method in post-hoc manner.</p_value_desc>
            <method>Pairwise comparison based on ANCOVA</method>
            <method_desc>ANCOVA model with terms of treatment, prior antihyperglycemic medication status and baseline was used for pairwise comparison</method_desc>
            <param_type>Least-squares Mean Difference</param_type>
            <param_value>-23.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-29.8</ci_lower_limit>
            <ci_upper_limit>-16.6</ci_upper_limit>
            <estimate_desc>ANCOVA model with terms of treatment, prior antihyperglycemic medication status and baseline was used to estimate difference of two groups and its 95% confidence interval</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity among pairwise comparisons of sitagliptin groups against placebo was adjusted by Bonferroni method in post-hoc manner.</p_value_desc>
            <method>Pairwise comparison based on ANCOVA</method>
            <method_desc>ANCOVA model with terms of treatment, prior antihyperglycemic medication status and baseline was used for pairwise comparison</method_desc>
            <param_type>Least-squares Mean Difference</param_type>
            <param_value>-20.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-27.4</ci_lower_limit>
            <ci_upper_limit>-14.3</ci_upper_limit>
            <estimate_desc>ANCOVA model with terms of treatment, prior antihyperglycemic medication status and baseline was used to estimate difference of two groups and its 95% confidence interval</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity among pairwise comparisons of sitagliptin groups against placebo was adjusted by Bonferroni method in post-hoc manner.</p_value_desc>
            <method>Pairwise comparison based on ANCOVA</method>
            <method_desc>ANCOVA model with terms of treatment, prior antihyperglycemic medication status and baseline was used for pairwise comparison</method_desc>
            <param_type>Least-squares Mean Difference</param_type>
            <param_value>-17.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-24.2</ci_lower_limit>
            <ci_upper_limit>-11.2</ci_upper_limit>
            <estimate_desc>ANCOVA model with terms of treatment, prior antihyperglycemic medication status and baseline was used to estimate difference of two groups and its 95% confidence interval</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity among pairwise comparisons of sitagliptin groups against placebo was adjusted by Bonferroni method in post-hoc manner.</p_value_desc>
            <method>Pairwise comparison based on ANCOVA</method>
            <method_desc>ANCOVA model with terms of treatment, prior antihyperglycemic medication status and baseline was used for pairwise comparison</method_desc>
            <param_type>Least-squares Mean Difference</param_type>
            <param_value>-15.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-22.3</ci_lower_limit>
            <ci_upper_limit>-9.6</ci_upper_limit>
            <estimate_desc>ANCOVA model with terms of treatment, prior antihyperglycemic medication status and baseline was used to estimate difference of two groups and its 95% confidence interval</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Reported overdoses, regardless of association with reported adverse events, were considered as serious adverse events in this study. The patients for whom the event of overdose was reported had no concomitant AEs with the overdose.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sitagliptin 25 mg QD</title>
          <description>The Sitagliptin 25 mg group includes data from all patients randomized to receive treatment with sitagliptin 25 mg orally once daily (QD=once daily).</description>
        </group>
        <group group_id="E2">
          <title>Sitagliptin 50 mg QD</title>
          <description>The Sitagliptin 50 mg group includes data from all patients randomized to receive treatment with sitagliptin 50 mg orally once daily (QD=once daily).</description>
        </group>
        <group group_id="E3">
          <title>Sitagliptin 100 mg QD</title>
          <description>The Sitagliptin 100 mg group includes data from all patients randomized to receive treatment with sitagliptin 100 mg orally once daily (QD=once daily).</description>
        </group>
        <group group_id="E4">
          <title>Sitagliptin 200 mg QD</title>
          <description>The Sitagliptin 200 mg group includes data from all patients randomized to receive treatment with sitagliptin 200 mg orally once daily (QD=once daily).</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>The Placebo group includes data from all patients randomized to receive treatment with matching placebo orally once daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 8.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0"/>
                <counts group_id="E2" subjects_affected="1"/>
                <counts group_id="E3" subjects_affected="0"/>
                <counts group_id="E4" subjects_affected="2"/>
                <counts group_id="E5" subjects_affected="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 8.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31"/>
                <counts group_id="E2" subjects_affected="25"/>
                <counts group_id="E3" subjects_affected="32"/>
                <counts group_id="E4" subjects_affected="20"/>
                <counts group_id="E5" subjects_affected="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

